Ultragenyx Pharmaceutical (NASDAQ: RARE) insider transactions
In the twelve months to 10 November 2026, executives and directors of Ultragenyx Pharmaceutical reported 28 open-market sales of 164,521 shares ($3.8m) and 0 open-market purchases, by 9 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 15 October 2026 | Horn Howard | Chief Financial Officer | Open-market sale | −7,066 | $15.27 | 89,229 | Form 4 |
| 15 September 2026 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Open-market sale | −1,283 | $13.57 | 67,863 | Form 4 |
| 3 September 2026 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Open-market sale | −161 | $13.99 | 69,146 | Form 4 |
| 3 August 2026 | Horn Howard | Chief Financial Officer | Open-market sale | −4,696 | $24.92 | 96,295 | Form 4 |
| 3 August 2026 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Open-market sale | −1,900 | $24.92 | 92,562 | Form 4 |
| 1 July 2026 | Horn Howard | Chief Financial Officer | Open-market sale | −4,698 | $33.13 | 100,991 | Form 4 |
| 15 June 2026 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Open-market sale | −1,899 | $24.62 | 94,462 | Form 4 |
| 15 June 2026 | Sanders Corazon (Corsee) D. | Director | Open-market sale | −2,000 | $25.05 | 21,095 | Form 4 |
| 1 June 2026 | Horn Howard | Chief Financial Officer | Open-market sale | −4,653 | $23.77 | 105,689 | Form 4 |
| 18 May 2026 | Suliman Shehnaaz | Director | Open-market sale | −5,740 | $25.12 | 27,951 | Form 4 |
| 14 May 2026 | Dunsire Deborah | Director | Grant or award | +7,751 | — | 38,566 | Form 4 |
| 14 May 2026 | Welch Daniel G | Director | Grant or award | +7,751 | — | 40,441 | Form 4 |
| 14 May 2026 | Narachi Michael | Director | Grant or award | +7,751 | — | 40,441 | Form 4 |
| 14 May 2026 | Fust Matthew K | Director | Grant or award | +7,751 | — | 33,696 | Form 4 |
| 14 May 2026 | Suliman Shehnaaz | Director | Grant or award | +7,751 | — | 33,691 | Form 4 |
| 14 May 2026 | Sanders Corazon (Corsee) D. | Director | Grant or award | +7,751 | — | 23,095 | Form 4 |
| 14 May 2026 | Ray Amrit | Director | Grant or award | +7,751 | — | 31,116 | Form 4 |
| 5 May 2026 | Crombez Eric | EVP and Chief Medical Officer | Open-market sale | −344 | $24.96 | 111,189 | Form 4 |
| 1 May 2026 | Horn Howard | Chief Financial Officer | Open-market sale | −4,683 | $24.90 | 110,342 | Form 4 |
| 22 April 2026 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Grant or award | +20,241 | — | 68,911 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Ultragenyx Pharmaceutical page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.